MCL1 and Miyoshi myopathy: A study conducted by Slomp et al. showed that primary BM MM cells from patients carrying 1q21 amp were significantly more sensitive to treatment with MCL-1 inhibitor S63845 than MM cells from patients without this chromosomal aberration, suggesting that S63845 may be more effective in MM patients with 1q21 amp [53].